Waltham, Mass. — September 8, 2025 — Leads & Copy — ElevateBio has appointed Larry Lockwood, Ph.D., as Chief Commercial Officer. Lockwood brings over 20 years of leadership experience and technical expertise.
In his new role, Lockwood will lead commercial strategy to accelerate revenue growth by expanding partnerships at BaseCamp, ElevateBio’s cGMP manufacturing business, and monetizing the technologies and platform of Life Edit, its gene editing and R&D technology business.
Before joining ElevateBio, Lockwood held leadership positions at Aldevron, part of Danaher Life Sciences, most recently as Global Head of CDMO Strategy. He holds a Ph.D. in Organic Chemistry from Rensselaer Polytechnic Institute and a B.S. in Chemistry from Towson State University.
ElevateBio is focused on transformative genetic medicines. The company commercializes its technologies, manufacturing capabilities, and expertise through partnerships. The ElevateBio ecosystem combines Life Edit with BaseCamp, its end-to-end genetic medicine process development and cGMP manufacturing business.
Investor contact: Catherine Hu, chu@elevate.bio; Media contact: DJ Webster, dwebster@elevate.bio
Source: ElevateBio
